LNX2

Across TCGA pan-cancer cohorts, LNX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LNX2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LNX2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LNX2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where LNX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.219	0.877	.010	19	view →
UCEC	OS	Median	III,IV	0.547	1.000	.037	4	view →
HNSC	DFS	Tertile	All	0.897	1.000	.021	4	view →
LSCC	DFS	Median	All	0.815	0.614	.029	2	view →
LUAD	DFS	Median	II,III,IV	0.788	0.401	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LNX2–PDAC (OS)

Open the PDAC breakdown →